<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004767</url>
  </required_header>
  <id_info>
    <org_study_id>ATRI-004</org_study_id>
    <secondary_id>R01AG053798</secondary_id>
    <nct_id>NCT04004767</nct_id>
  </id_info>
  <brief_title>TRC-PAD Program: In-Clinic Trial-Ready Cohort</brief_title>
  <acronym>TRC-PAD</acronym>
  <official_title>Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Therapeutic Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Clinical Trials Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cleveland Clinic Lou Ruvo Center for Brain Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the TRC-PAD study is to develop a large, well-characterized,&#xD;
      biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention&#xD;
      trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and&#xD;
      biomarker confirmation. Participants with known biomarker status may have direct referral to&#xD;
      the Trial-Ready Cohort.&#xD;
&#xD;
      If you are interested in being selected for the TRC-PAD study, you should first enroll in the&#xD;
      APT Webstudy (https://www.aptwebstudy.org/welcome).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRC-PAD study is short for the &quot;Trial-Ready Cohort for the Prevention of Alzheimer's&#xD;
      Dementia&quot;. The purpose of the TRC-PAD study is to find many people (also called a &quot;cohort&quot;)&#xD;
      who are interested in participating in clinical trials aimed at discovering treatments that&#xD;
      will reduce the risk of developing Alzheimer's dementia. TRC-PAD will help researchers enroll&#xD;
      participants into these trials quickly to allow new treatments to be discovered as soon as&#xD;
      possible.&#xD;
&#xD;
      The TRC-PAD study is for individuals, age 50 and older, who may be at increased risk for&#xD;
      memory loss caused by Alzheimer's disease. To join the TRC-PAD study, you first need to be&#xD;
      invited to complete an in-person TRC-PAD visit.&#xD;
&#xD;
      How can I be invited to an in-person visit for TRC-PAD? Members of the Alzheimer Prevention&#xD;
      Trials (APT) Webstudy complete online questionnaires and memory tests. The results of these&#xD;
      tests will identify individuals as being eligible for an in-person TRC-PAD visit. If you are&#xD;
      not enrolled in the APT Webstudy, you may be invited to an in-person visit for TRC-PAD&#xD;
      because other tests or procedures you have had suggest you might be eligible to participate.&#xD;
&#xD;
      How might the TRC-PAD Study help researchers learn more about Alzheimer's disease dementia?&#xD;
      Alzheimer's disease remains one of the most important medical conditions for which there is&#xD;
      no treatment. Among the top ten causes of death, Alzheimer's disease is the only one that&#xD;
      cannot be prevented, cured, or even slowed. To change this, researchers are conducting&#xD;
      clinical trials to find new treatments. These trials need to study large numbers of&#xD;
      individuals and follow participants over long periods of time. The goal of TRC-PAD is to&#xD;
      identify individuals for these trials. TRC-PAD will find a group of people who may be&#xD;
      &quot;at-risk&quot; for developing Alzheimer's dementia in the future and are appropriate for&#xD;
      prevention trials.&#xD;
&#xD;
      How does TRC-PAD decide that I may have an increased risk for developing Alzheimer's&#xD;
      dementia? A person's risk for developing Alzheimer's dementia is determined by a number of&#xD;
      factors including family history, performance on memory tests, and biological tests called&#xD;
      biomarkers. Biomarkers are measurements in parts of the body - like blood tests or brain&#xD;
      scans - to help assess the presence of, or potential to develop, a disease.&#xD;
&#xD;
      If I decide to join TRC-PAD, what happens? Individuals in the TRC-PAD study will complete&#xD;
      several assessments to see if they qualify to join the cohort. This will include biomarker&#xD;
      testing (via Positron Emission Tomography (PET) brain scan or spinal fluid collection), tests&#xD;
      of memory and thinking, questionnaires about daily functioning, mood and behavior, genetic&#xD;
      testing and routine blood and urine tests. Individuals who are determined to eligible to&#xD;
      enroll in TRC will come back to the clinic every 6 months for brief longitudinal follow-up&#xD;
      visits with questionnaires and testing until that individual qualifies for a clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment into preclinical and prodromal AD clinical trials</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimization of adaptive risk algorithm to predict risk of amyloid positivity</measure>
    <time_frame>5 years</time_frame>
    <description>The TRC-PAD program aims to optimize an innovative, adaptive risk algorithm to efficiently identify the most appropriate trial participants. Once optimized, this algorithm will be able to select amyloid positive individuals (and eventually tau and other neurodegenerative biomarkers) with &gt;75% accuracy, greatly reducing future costly biomarker screen fails.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Preclinical Alzheimer's Disease</condition>
  <condition>Prodromal Alzheimer's Disease</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>TRC-PAD Cohort</arm_group_label>
    <description>Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Urine, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AD biomarker confirmed individuals who may be at an increased risk for memory loss caused&#xD;
        by Alzheimer's disease dementia. Individuals at highest risk within the APT Webstudy will&#xD;
        be referred for an in-person TRC-PAD visit. Individuals with known biomarker status may&#xD;
        qualify for a direct referral to the trial-ready cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated availability and willingness to comply with all study procedures until referred&#xD;
             to a clinical trial&#xD;
&#xD;
          3. Age 50-85 (inclusive)&#xD;
&#xD;
          4. Global Clinical Dementia Rating (CDR) score of 0 or 0.5 and no diagnosis of dementia&#xD;
&#xD;
          5. Has a study partner that is willing to participate as a source of information and has&#xD;
             at least weekly contact with the participant (contact can be in-person, via telephone&#xD;
             or electronic communication). The study partner must have sufficient contact such that&#xD;
             the investigator feels the study partner can provide meaningful information about the&#xD;
             participant's daily function.&#xD;
&#xD;
          6. In good general health as evidenced by medical history&#xD;
&#xD;
          7. Adequate visual and auditory acuity to allow neuropsychological testing&#xD;
&#xD;
          8. Fluent in English or Spanish&#xD;
&#xD;
          9. For females who are not surgically sterile or post-menopausal by two years, receiving&#xD;
             a Positron Emission Tomography (PET) scan for amyloid biomarker confirmation: negative&#xD;
             pregnancy test prior to amyloid PET scan&#xD;
&#xD;
         10. Completed six grades of education or has a good work history&#xD;
&#xD;
         11. Evidence of elevated or intermediate (subthreshold) levels brain amyloid as assessed&#xD;
             by central review of amyloid PET or cerebrospinal fluid (CSF) data. Prior amyloid&#xD;
             testing results may be used with approval from the Coordinating Center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with an another anti-amyloid investigational anti-amyloid drug or other&#xD;
             experimental intervention within 12 months. Use of aducanumab or other approved&#xD;
             anti-amyloid treatments allowed if stable for at least 3 months.&#xD;
&#xD;
          2. Enrolled in another interventional clinical trial within the last 12 weeks&#xD;
&#xD;
          3. Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's&#xD;
             disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus,&#xD;
             brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma,&#xD;
             multiple sclerosis, or history of significant head trauma followed by persistent&#xD;
             neurologic deficits or known structural brain abnormalities.&#xD;
&#xD;
          4. Major depression, bipolar disorder as described in DSM-V within the past 1 year or&#xD;
             psychotic features, agitation or behavioral problems within 3 months, which could lead&#xD;
             to difficulty complying with the protocol&#xD;
&#xD;
          5. History of schizophrenia (DSM V criteria)&#xD;
&#xD;
          6. History of alcohol or substance abuse or dependence within the past 2 years (DSM V&#xD;
             criteria)&#xD;
&#xD;
          7. Clinically significant or unstable medical condition, including uncontrolled&#xD;
             hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal,&#xD;
             hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may&#xD;
             either put the participant at risk because of participation in the study, or influence&#xD;
             the results, or the participant's ability to participate in the study.&#xD;
&#xD;
          8. History within the last 3 years of a primary or recurrent malignant disease with the&#xD;
             exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in&#xD;
             situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer&#xD;
             with normal prostate-specific antigen post-treatment&#xD;
&#xD;
          9. Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that&#xD;
             might interfere with the study. A low B12 is exclusionary, unless follow-up labs&#xD;
             (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not&#xD;
             physiologically significant.&#xD;
&#xD;
         10. Clinically significant abnormalities in screening laboratories or ECG.&#xD;
&#xD;
         11. For participants undergoing CSF collection: a current blood clotting or bleeding&#xD;
             disorder, or significantly abnormal PT or PTT at screening or if on anti-coagulation&#xD;
             (e.g. warfarin)&#xD;
&#xD;
         12. Participants whom the Site PI deems to be otherwise ineligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Alzheimer's Therapeutic Research Institute (ATRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reisa Sperling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>APT / TRC Recruitment Team</last_name>
    <phone>858-877-3135</phone>
    <email>info@aptwebstudy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Geldmacher, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Tauchmann</last_name>
      <phone>602-839-4891</phone>
      <email>Daniela.Tauchmann@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>David Weidman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadira Trncic</last_name>
      <phone>623-832-6590</phone>
      <email>Nadira.Trncic@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Alireza Atri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center, Inc</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judy Galindo</last_name>
      <email>judy@sunvalleyb.com</email>
    </contact>
    <investigator>
      <last_name>Bernardo Ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Vides</last_name>
      <phone>949-824-3250</phone>
      <email>byanez@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Grill, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Becerra</last_name>
      <phone>329-442-7594</phone>
      <email>Mauricio.Becerra@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lyn Than</last_name>
      <phone>329-442-7603</phone>
      <email>Lyn.Than@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lon Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>945985900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Gunnoud</last_name>
      <phone>203-764-8107</phone>
      <email>carol.gunnoud@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Waldner</last_name>
      <phone>203-764-8107</phone>
      <email>Emma.waldner@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher H van Dyck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200072145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly McCann</last_name>
      <phone>202-687-0413</phone>
      <email>keb53@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Raymond Scott Turner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Thomas</last_name>
      <phone>904-953-7739</phone>
    </contact>
    <contact_backup>
      <last_name>Sylvia Grant</last_name>
      <phone>904-953-7739</phone>
      <email>grant.sylvia@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neill Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wien Center for Alzheimer's Disease</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie A Rodriguez</last_name>
      <phone>305-674-2121</phone>
      <phone_ext>56771</phone_ext>
      <email>Rosemarie.Rodriguez@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Ranjan Duara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gonzalez MD &amp; Aswad MD Health Services</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amado Gonzalez</last_name>
      <email>amado@optimusu.com</email>
    </contact>
    <contact_backup>
      <last_name>Fermin Nieto</last_name>
      <phone>305-702-0024</phone>
      <email>fermin@optimusu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yaneicy Gonzalez Rojas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Jackson</last_name>
      <phone>352-629-2662</phone>
      <phone_ext>105</phone_ext>
      <email>carol.jackson@renstar.net</email>
    </contact>
    <investigator>
      <last_name>Anette Nieves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Ashley</last_name>
      <phone>352-629-9392</phone>
      <email>alyssa.ashley@renstar.net</email>
    </contact>
    <investigator>
      <last_name>Anette Nieves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ripley</last_name>
      <email>steven.ripley@globalaes.com</email>
    </contact>
    <contact_backup>
      <last_name>Christina Kaplun</last_name>
      <phone>407-210-1296</phone>
      <email>christina.kaplun@globalaes.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Taylor, II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Tierney</last_name>
      <email>andiet@progressivemedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alexander White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jetliza Lesmes</last_name>
      <phone>561-381-9060</phone>
      <email>jlesmes@ergclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Yolanda Gonzalez</last_name>
      <phone>561-374-8461</phone>
      <phone_ext>1141</phone_ext>
      <email>ygonzalez@ergclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paayal Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Health Byrd Alzheimer Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>336134808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juris Janavs</last_name>
      <phone>813-396-0637</phone>
      <email>jjanavs@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research, The Villages</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162-7116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayley Molin</last_name>
      <phone>352-261-0901</phone>
      <email>Hayley.Molin@globalaes.com</email>
    </contact>
    <contact_backup>
      <last_name>Desiree Maier</last_name>
      <email>Desiree.Maier@globalaes.com</email>
    </contact_backup>
    <investigator>
      <last_name>Uzma Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charter Research, LLC</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Harrison</last_name>
      <phone>407-337-1000</phone>
      <email>liz.harrison@CharterResearch.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbus Memory Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piper Gilley</last_name>
      <phone>706-653-8455</phone>
      <email>research7@stork.md</email>
    </contact>
    <investigator>
      <last_name>Jonathan L Liss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittanie Mure</last_name>
      <phone>312-503-5674</phone>
      <email>brittanie.muse@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Shepard</last_name>
      <email>robert-shepard@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Grant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Liambotis</last_name>
      <phone>312-563-0523</phone>
      <email>Peter_J_Liambotis@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Neelum Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kala Hall</last_name>
      <phone>317-963-1867</phone>
      <email>kalhall@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Farlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Brook</last_name>
      <phone>901-866-9252</phone>
      <email>dbrook@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Townley, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>405042681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hope Esposito</last_name>
      <phone>859-323-4547</phone>
      <email>hope.esposito@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Jicha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212242764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Horn</last_name>
      <phone>410-550-9020</phone>
      <email>shorn8@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>21155804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Kuney</last_name>
      <phone>617-732-7992</phone>
      <email>skuney@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Gad Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Donald S. Marks, MD., P.C.</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Karas</last_name>
      <email>lizzyk@dsmmdpc.com</email>
    </contact>
    <investigator>
      <last_name>Donald S. Marks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Mackenzie</last_name>
      <phone>734-232-2415</phone>
      <email>spearsl@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Judith Heidebrink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Etbauer</last_name>
      <phone>507-284-1324</phone>
      <email>etbauer.kimberly@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>631082215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Santos</last_name>
      <phone>314-286-2363</phone>
      <email>mhsantos@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Schrader</last_name>
      <phone>314-273-3866</phone>
      <email>stacey.schrader@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joy Snider, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>891060100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grey Rivera</last_name>
      <email>riverag@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Dylan Wint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmeralda Morales</last_name>
      <phone>585-760-6562</phone>
      <email>esmeraldamorales@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail O'Connell</last_name>
      <phone>336-716-7976</phone>
      <email>abigail.oconnell@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Craft, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>441224312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Posan</last_name>
      <email>Megan.Posan2@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Rajeet Shrestha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grey Rivera</last_name>
      <phone>702-701-7967</phone>
      <email>riverag@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Chelsea Jenings</last_name>
      <phone>702-483-6029</phone>
      <email>jenninc3@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Babak Tousi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Icenhour</last_name>
      <phone>614-293-6882</phone>
      <email>jennifer.icenhour@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972393011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Spoden</last_name>
      <phone>503-494-0976</phone>
      <email>spoden@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Aimee Pierce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Donofry</last_name>
      <phone>215-957-9250</phone>
      <email>alyssadonofry.ana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Weisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Weiss</last_name>
      <phone>215-615-3133</phone>
      <email>allison.weiss@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjeev Vaishnavi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Fogerty</last_name>
      <phone>401-444-0085</phone>
      <email>TFogerty@Lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Chuang-Kuo Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital Memory and Aging Program</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Daneault</last_name>
      <phone>860-908-6738</phone>
      <email>KDaneault@buttler.org</email>
    </contact>
    <investigator>
      <last_name>Athene Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Browning</last_name>
      <phone>214-645-1972</phone>
      <email>Amy.browning@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brendan Kelley</last_name>
      <phone>214-648-2955</phone>
      <email>Brendan.kelley@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brendan Kelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Sciences Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilma Burns</last_name>
      <phone>817-735-2948</phone>
      <email>Wilma.Burns@unthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Haydee Izurieta-Munoz</last_name>
      <phone>817-735-2948</phone>
      <email>Haydee.IzurietaMunoz@unthsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leigh Johnson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Stanley</last_name>
      <email>jfish@ncrinc.net</email>
    </contact>
    <investigator>
      <last_name>John Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Knappe</last_name>
      <phone>804-672-2133</phone>
      <phone_ext>52</phone_ext>
      <email>lknappe@ncrinc.net</email>
    </contact>
    <investigator>
      <last_name>John Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington / Seattle Institute for Biomedical and Clinical Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Ranta</last_name>
      <phone>206-764-2339</phone>
      <email>rantaa@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jon Reid</last_name>
      <email>jon.reid@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elaine Peskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Huynh</last_name>
      <email>jhuynh@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Carlsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aptwebstudy.org/welcome</url>
    <description>APT Webstudy</description>
  </link>
  <link>
    <url>https://keck.usc.edu/atri/research/studies/</url>
    <description>ATRI Studies</description>
  </link>
  <link>
    <url>https://www.actcinfo.org/</url>
    <description>Alzheimer's Clinical Trials Consortium</description>
  </link>
  <reference>
    <citation>Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA; Alzheimer's Disease Cooperative Study. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr;72(4):446-54. doi: 10.1001/jamaneurol.2014.3375. Erratum in: JAMA Neurol. 2015 May;72(5):608.</citation>
    <PMID>25706191</PMID>
  </reference>
  <reference>
    <citation>Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid Î². Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.</citation>
    <PMID>28253478</PMID>
  </reference>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>October 31, 2022</last_update_submitted>
  <last_update_submitted_qc>October 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Prevention</keyword>
  <keyword>Observational</keyword>
  <keyword>Trial-Ready Cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

